Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Ocana

Showing results (51-60 of 98) with videos related to

Pageof 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 3, 2015
Influence of censoring on conclusions of trials for women with metastatic breast cancerArnoud J Templeton, Olga Ace, Eitan Amir, et al.
Cancer Medicine|September 5, 2020
Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumorsRamy R Saleh, Nicholas Meti, Domen Ribnikar, et al.
Oncotarget|March 31, 2018
Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancerAriadna Tibau, Geòrgia Anguera, Fernando Andrés-Pretel, et al.
The Lancet. Oncology|December 8, 2016
Relevance of randomised controlled trials in oncologyIan F Tannock, Eitan Amir, Christopher M Booth, et al.
Critical Reviews in Oncology/Hematology|July 5, 2020
Potential insights from population kinetic assessment of progression-free survival curvesDavid J Stewart, Dominick Bosse, Andrew Robinson, et al.
Plos Computational Biology|May 26, 2026
Cooperative molecular interaction networks govern PARP1 inhibitor selectivity and binding affinityAlejandro Feito, Natàlia DeMoya-Valenzuela, Cristian Privat, et al.
Scientific Reports|April 7, 2019
Mapping Bromodomains in breast cancer and association with clinical outcomeJavier Pérez-Pena, Raquel Páez, Cristina Nieto-Jiménez, et al.
Molecular Diagnosis & Therapy|March 2, 2017
Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer DrugsAriadna Tibau, Laura Díez-González, Beatriz Navarro, et al.
Cancers|August 16, 2020
Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1Francisco J Cimas, Arancha Manzano, Mariona Baliu-Piqué, et al.
Scientific Reports|October 19, 2019
Identification and Validation of a Novel Biologics Target in Triple Negative Breast CancerVikram B Wali, Gauri A Patwardhan, Vasiliki Pelekanou, et al.
Pageof 10

Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|March 3, 2015
Influence of censoring on conclusions of trials for women with metastatic breast cancerArnoud J Templeton, Olga Ace, Eitan Amir, et al.
Cancer Medicine|September 5, 2020
Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumorsRamy R Saleh, Nicholas Meti, Domen Ribnikar, et al.
Oncotarget|March 31, 2018
Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancerAriadna Tibau, Geòrgia Anguera, Fernando Andrés-Pretel, et al.
The Lancet. Oncology|December 8, 2016
Relevance of randomised controlled trials in oncologyIan F Tannock, Eitan Amir, Christopher M Booth, et al.
Critical Reviews in Oncology/Hematology|July 5, 2020
Potential insights from population kinetic assessment of progression-free survival curvesDavid J Stewart, Dominick Bosse, Andrew Robinson, et al.
Plos Computational Biology|May 26, 2026
Cooperative molecular interaction networks govern PARP1 inhibitor selectivity and binding affinityAlejandro Feito, Natàlia DeMoya-Valenzuela, Cristian Privat, et al.
Scientific Reports|April 7, 2019
Mapping Bromodomains in breast cancer and association with clinical outcomeJavier Pérez-Pena, Raquel Páez, Cristina Nieto-Jiménez, et al.
Molecular Diagnosis & Therapy|March 2, 2017
Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer DrugsAriadna Tibau, Laura Díez-González, Beatriz Navarro, et al.
Cancers|August 16, 2020
Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1Francisco J Cimas, Arancha Manzano, Mariona Baliu-Piqué, et al.
Scientific Reports|October 19, 2019
Identification and Validation of a Novel Biologics Target in Triple Negative Breast CancerVikram B Wali, Gauri A Patwardhan, Vasiliki Pelekanou, et al.
Pageof 10